A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)

Summary

This phase I study is designed to evaluate absorption, metabolism and excretion (AME) profiles of \[14C\]-DZD8586, to determine the routes, rates of elimination, and mass balance of DZD8586 in healthy adult male participants. Participants will be administered a single oral dose of 50 mg of \[14C\]-DZD8586 (containing radioactive dose \~ 100 μCi) as a suspension.

Timeline

Start

2026-03-16

Primary completion

2026-03-27

Completion

2026-04-06

Drugs

Indications